Dyadic International Inc (DYAI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Dyadic International Inc stock (DYAI) is currently trading at $0.84. Dyadic International Inc PS ratio (Price-to-Sales) is 10.18. Analyst consensus price target for DYAI is $5.67. WallStSmart rates DYAI as Sell.
- DYAI PE ratio analysis and historical PE chart
- DYAI PS ratio (Price-to-Sales) history and trend
- DYAI intrinsic value — DCF, Graham Number, EPV models
- DYAI stock price prediction 2025 2026 2027 2028 2029 2030
- DYAI fair value vs current price
- DYAI insider transactions and insider buying
- Is DYAI undervalued or overvalued?
- Dyadic International Inc financial analysis — revenue, earnings, cash flow
- DYAI Piotroski F-Score and Altman Z-Score
- DYAI analyst price target and Smart Rating
Dyadic International Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Dyadic International Inc (DYAI) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Dyadic International Inc (DYAI) Key Strengths (1)
Revenue surging 150.50% year-over-year
Supporting Valuation Data
Dyadic International Inc (DYAI) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 10.2x annual revenue
Very expensive at 12.8x book value
Very low institutional interest at 11.39%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Dyadic International Inc (DYAI) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 150.50%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (10.18), Price/Book (12.78) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -422.60%, Operating Margin at -177.20%, Profit Margin at -134.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -422.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 150.50% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
DYAI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
DYAI's Price-to-Sales ratio of 10.18x trades at a deep discount to its historical average of 76.4x (9th percentile). The current valuation is 95% below its historical high of 212.25x set in Jun 2020, and 26% above its historical low of 8.08x in Feb 2026. Over the past 12 months, the PS ratio has compressed from ~14.2x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Dyadic International Inc (DYAI) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Dyadic International Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 4M with 151% growth year-over-year. The company is currently unprofitable, posting a -134.8% profit margin.
Key Findings
Revenue growing at 151% YoY, reaching 4M. This pace significantly outperforms most BIOTECHNOLOGY peers.
The company is unprofitable with a -134.8% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Dyadic International Inc maintain 151%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Dyadic International Inc.
Bottom Line
Dyadic International Inc is a high-conviction growth story with revenue accelerating at 151% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -134.8% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Dyadic International Inc(DYAI)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Dyadic International, Inc., a biotechnology platform company, develops, produces and sells enzymes and other proteins in the United States. The company is headquartered in Jupiter, Florida.